Asher Hussain, MD
Nephrology · Trenton, NJNPI 1780921288
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,043 of the $5,862 with a category attached, or 86.0%. It is spread thinly across 20 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations.
Across 356 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$949
- AstraZeneca$726
- OPKO Pharmaceuticals, LLC$619
- GSK$460
- Vifor Pharma, Inc.$458
- Bayer$435
- plus $2K from 14 others
What the payments were for
- Consulting fees$5219%
- Food & beverage$5,04386%
- Education$2985%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 69 | $949 |
| AstraZeneca(2 entities) | 39 | $726 |
| OPKO Pharmaceuticals, LLC | 75 | $619 |
| GSK | 18 | $460 |
| Vifor Pharma, Inc. | 28 | $458 |
| Bayer | 26 | $435 |
| Ardelyx, Inc. | 17 | $346 |
| Otsuka America Pharmaceutical, Inc. | 16 | $317 |
| Travere Therapeutics, Inc. | 1 | $285 |
| Amgen(2 entities) | 11 | $260 |
| Daiichi Sankyo Inc. | 11 | $183 |
| Akebia Therapeutics Inc | 11 | $181 |
| Mallinckrodt Hospital Products Inc. | 6 | $176 |
| Calliditas Therapeutics US Inc. | 8 | $148 |
| Novartis | 5 | $85 |
| Aurinia Pharma U.S., Inc. | 5 | $76 |
| Boehringer Ingelheim | 4 | $60 |
| Sanofi | 3 | $53 |
| Mallinckrodt Enterprises LLC | 2 | $28 |
| Baxter Healthcare | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,862 in reported general payments places this provider in the 85th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 27 | $89,334 |
| FarxigaDapagliflozin Propanediol | 115 | $67,891 |
| XphozahTenapanor Hcl | 12 | $53,199 |
| KerendiaFinerenone | 50 | $42,782 |
| RayaldeeCalcifediol | 27 | $33,072 |
| LokelmaSodium Zirconium Cyclosilicate | 32 | $26,108 |
| Lanthanum Carbonate | 14 | $15,326 |
| Sevelamer Carbonate | 80 | $10,731 |
| ProcritEpoetin Alfa | 15 | $8,350 |
| Calcitriol | 90 | $2,272 |
| Nifedipine ErNifedipine | 22 | $856 |
| Bumetanide | 26 | $734 |
| Calcium Acetate | 17 | $697 |
| Furosemide | 52 | $279 |
| Hydralazine Hcl | 22 | $212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $726 | $93,999147 claims |
| Fresenius USA Marketing, Inc.Velphoro | $949 | $89,33427 claims |
| BayerKerendia | $435 | $42,78250 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $619 | $33,07227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Trenton
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Arif AsifNeptune$42K
- Joseph AlbaneseBrick$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.